SCHEMBL7202693

SCHEMBL7202693

COc1cccc(OC2CCN(S(=O)(=O)C3CCNCC3(O)C(=O)NO)CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.44
PROKR1 Q8TCW9 1/20 0.44
EPHX2 P34913 1/20 0.42
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MMP3 P08254 1/20 0.39
MMP10 P09238 1/20 0.39
RAB9A P51151 3/20 0.39
KMT2A Q03164 1/20 0.38
MAPT P10636 1/20 0.38
NPC1 O15118 1/20 0.38
PKM P14618 1/20 0.38
HTR2C P28335 1/20 0.37
ADAM17 P78536 2/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CCR3 P51677 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7200949 0.91 MMP13 (0.45) FPR2PROKR1EPHX2POLBALDH1A1
SCHEMBL7201546 0.91 SMN1; SMN2 (0.48) FPR2PROKR1EPHX2SMN1; SMN2MMP3
SCHEMBL7206963 0.89 HTR2C (0.49) FPR2PROKR1EPHX2RAB9AHTR2C
SCHEMBL7202653 0.89 MLNR (0.45) SMN1; SMN2RAB9AKMT2AHTR2CHRH3
SCHEMBL7199648 0.88 HTR2C (0.44) FPR2PROKR1EPHX2MMP3HTR2C
SCHEMBL7204170 0.87 HTR2C (0.48) ALDH1A1MMP3MMP10PKMHTR2C
SCHEMBL7207975 0.87 PKM (0.42) POLBALDH1A1PKMADAM17MMP1
SCHEMBL7202570 0.85 EPHX2 (0.41) EPHX2POLBALDH1A1MMP3MMP10
SCHEMBL7200991 0.85 MMP13 (0.43) FPR2PROKR1EPHX2SMN1; SMN2KMT2A
SCHEMBL7201599 0.84 MMP13 (0.52) FPR2PROKR1POLBMMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 FPR2 3132/4885PROKR1 1348/4885EPHX2 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.